Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $280,238.40 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 38,922 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40. Following the sale, the insider owned 4,279,426 shares of the company’s stock, valued at $30,811,867.20. This trade represents a 0.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.

Entrada Therapeutics Trading Up 3.3%

Shares of TRDA stock opened at $7.30 on Thursday. The company has a market capitalization of $284.24 million, a P/E ratio of -1.84 and a beta of -0.25. The business’s 50 day moving average is $7.08 and its two-hundred day moving average is $9.23. Entrada Therapeutics, Inc. has a twelve month low of $5.02 and a twelve month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. As a group, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Several institutional investors have recently made changes to their positions in TRDA. Alliancebernstein L.P. increased its holdings in shares of Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after buying an additional 1,620 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Entrada Therapeutics by 11.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,465 shares of the company’s stock valued at $246,000 after acquiring an additional 1,970 shares during the last quarter. Great Lakes Advisors LLC grew its holdings in Entrada Therapeutics by 5.5% during the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after acquiring an additional 2,239 shares in the last quarter. Quadrature Capital Ltd increased its position in shares of Entrada Therapeutics by 13.5% in the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after purchasing an additional 2,424 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Entrada Therapeutics by 3.6% in the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock valued at $505,000 after purchasing an additional 2,631 shares in the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on TRDA. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Roth Capital restated a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Finally, Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Entrada Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.